BIOMAT Database Logo BIOMAT Database Logo

[The comparative characteristics of parlodel, zinc sulfate and recombinant erythropoietin in treating uremic hypogonadism in patients on chronic hemodialysis]. 1992

A V Kukhtevich, and V M Ermolenko, and I I Dedov, and E P Gitel', and A F Buniatian, and G A Smirnova

UI MeSH Term Description Entries
D007006 Hypogonadism Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism). Hypergonadotropic Hypogonadism,Hypogonadism, Isolated Hypogonadotropic,Hypogonadotropic Hypogonadism,Hypogonadism, Hypergonadotropic,Hypogonadism, Hypogonadotropic
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010410 Penile Erection The state of the PENIS when the erectile tissue becomes filled or swollen (tumid) with BLOOD and causes the penis to become rigid and elevated. It is a complex process involving CENTRAL NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEMS; HORMONES; SMOOTH MUSCLES; and vascular functions. Tumescence, Penile,Nocturnal Penile Tumescence,Penile Tumescence,Erection, Penile,Penile Tumescence, Nocturnal,Tumescence, Nocturnal Penile
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.

Related Publications

A V Kukhtevich, and V M Ermolenko, and I I Dedov, and E P Gitel', and A F Buniatian, and G A Smirnova
Male hypogonadism of uremic patients on hemodialysis.
January 1988, Archives of andrology,
A V Kukhtevich, and V M Ermolenko, and I I Dedov, and E P Gitel', and A F Buniatian, and G A Smirnova
Effects of recombinant human erythropoietin on porphyrin metabolism in uremic patients on hemodialysis.
May 1996, Journal of the American Society of Nephrology : JASN,
A V Kukhtevich, and V M Ermolenko, and I I Dedov, and E P Gitel', and A F Buniatian, and G A Smirnova
The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
April 1992, International journal of hematology,
A V Kukhtevich, and V M Ermolenko, and I I Dedov, and E P Gitel', and A F Buniatian, and G A Smirnova
[Effect of recombinant human erythropoietin on hemodynamics in chronic hemodialysis patients].
December 1991, Nihon rinsho. Japanese journal of clinical medicine,
A V Kukhtevich, and V M Ermolenko, and I I Dedov, and E P Gitel', and A F Buniatian, and G A Smirnova
[Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
June 1990, Revista medica de Chile,
A V Kukhtevich, and V M Ermolenko, and I I Dedov, and E P Gitel', and A F Buniatian, and G A Smirnova
Management of anemia using recombinant human erythropoietin in patients on chronic hemodialysis.
December 1989, ANNA journal,
A V Kukhtevich, and V M Ermolenko, and I I Dedov, and E P Gitel', and A F Buniatian, and G A Smirnova
Recombinant human erythropoietin increases platelet aggregation in chronic hemodialysis patients.
May 1998, Thrombosis research,
A V Kukhtevich, and V M Ermolenko, and I I Dedov, and E P Gitel', and A F Buniatian, and G A Smirnova
Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients.
July 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation,
A V Kukhtevich, and V M Ermolenko, and I I Dedov, and E P Gitel', and A F Buniatian, and G A Smirnova
Relationship between uremic hypogonadism and zinc?
January 1979, Proceedings of the Clinical Dialysis and Transplant Forum,
A V Kukhtevich, and V M Ermolenko, and I I Dedov, and E P Gitel', and A F Buniatian, and G A Smirnova
Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients.
November 1991, Clinical nephrology,
Copied contents to your clipboard!